Small Company Offering and Sale of Securities Without Registration (d)
20 Novembro 2019 - 10:10AM
Edgar (US Regulatory)
o
NoneEntity Type | 0001583648 | Marika Inc. |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
Name of Issuer |
PIERIS PHARMACEUTICALS, INC. |
Jurisdiction of Incorporation/Organization |
NEVADA |
|
Year of Incorporation/Organization |
|
x
| Over Five Years Ago |
|
o
| Within Last Five Years (Specify Year) | |
|
o
| Yet to Be Formed | |
2. Principal Place of Business and Contact Information |
Name of Issuer | |
PIERIS PHARMACEUTICALS, INC. | |
Street Address 1 | Street Address 2 |
255 STATE STREET | 9TH FLOOR |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
BOSTON | MASSACHUSETTS | 02109 | 857-246-8998 |
Last Name | First Name | Middle Name |
Yoder | Stephen | S. |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Mousa | Ahmed | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Geraghty | James | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Richman | Michael | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Barbier, M.D., Ph.D. | Ann | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Bizzari, M.D. | Jean-Pierre | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Kiritsy | Christopher | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Kiener, D.Phil. | Peter | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Sherman, M.D. | Matthew | L. |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Said, Sc.D. | Maya | R. |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Bures | Tom | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Kaufmann, Ph.D. | Hitto | |
Street Address 1 | Street Address 2 |
255 State Street, 9th Floor | |
City | State/Province/Country | ZIP/Postal Code |
Boston | MASSACHUSETTS | 02109 |
Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
o
| Agriculture | | Health Care |
o
| Retailing |
| Banking & Financial Services | |
o
| Biotechnology |
o
| Restaurants |
|
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
|
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
|
o
| Investing | |
x
| Pharmaceuticals | |
o
| Telecommunications |
|
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
|
o
| Pooled Investment Fund
| | | | | Travel |
|
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| Real Estate | |
o
| Lodging & Conventions |
|
o
| Commercial | |
o
| Tourism & Travel Services |
|
o
| Construction | |
o
| Other Travel |
|
o
| REITS & Finance |
o
| Other |
|
o
| Residential | |
|
o
| Other Real Estate | |
o
| Business Services | |
| Energy | |
|
o
| Coal Mining | |
|
o
| Electric Utilities | |
|
o
| Energy Conservation | |
|
o
| Environmental Services | |
|
o
| Oil & Gas | |
|
o
| Other Energy | |
Revenue Range | Aggregate Net Asset Value Range |
o
| No Revenues |
o
| No Aggregate Net Asset Value |
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
o
| Over $100,000,000 |
o
| Over $100,000,000 |
x
| Decline to Disclose |
o
| Decline to Disclose |
o
| Not Applicable |
o
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
|
o
| Investment Company Act Section 3(c) |
x
| New Notice | Date of First Sale | 2019-11-06 |
o
| First Sale Yet to Occur |
Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
9. Type(s) of Securities Offered (select all that apply) |
o
| Pooled Investment Fund Interests |
x
| Equity |
o
| Tenant-in-Common Securities |
o
| Debt |
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
|
Clarification of Response (if Necessary) | |
|
Minimum investment accepted from any outside investor | $ 0 USD |
Recipient | Recipient CRD Number |
o
| None |
William Blair & Company | 1252 |
(Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| |
Street Address 1 | Street Address 2 |
150 North Riverside | |
City | State/Province/Country | ZIP/Postal Code |
Chicago | ILLINOIS | 60606-1594 |
State(s) of Solicitation |
o
| All States |
o
| Foreign/Non-US |
CALIFORNIA |
13. Offering and Sales Amounts |
Total Offering Amount | $ 32003108 USD |
o
Indefinite |
Total Amount Sold | $ 32003108 USD | |
Total Remaining to be Sold | $ 0 USD |
o
Indefinite |
|
Clarification of Response (if Necessary) |
|
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
| |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 9 |
15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 796062 USD |
o
| Estimate |
Finders' Fees | $ 0 USD |
o
| Estimate |
|
Clarification of Response (if Necessary) |
|
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| $ 0 USD |
o
Pieris Pharmaceuticals (NASDAQ:PIRS) Gráfico Histórico do Ativo De Mai 2024 até Jun 2024
Pieris Pharmaceuticals (NASDAQ:PIRS) Gráfico Histórico do Ativo De Jun 2023 até Jun 2024
Form 10-Q - Quarterly report [Sections 13 or 15(d)] Quarta, 15 de Maio de 2024 (3 semanas atrás) • Edgar (US Regulatory) |
Form 8-K - Current report Quinta, 9 de Maio de 2024 (4 semanas atrás) • Edgar (US Regulatory) |
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] Quarta, 14 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory) |
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] Quarta, 14 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory) |
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] Quarta, 14 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory) |
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] Sexta, 2 de Fevereiro de 2024 (4 meses atrás) • Edgar (US Regulatory) |
Form 8-K - Current report Quinta, 21 de Dezembro de 2023 (5 meses atrás) • Edgar (US Regulatory) |
Form 10-Q - Quarterly report [Sections 13 or 15(d)] Terça, 14 de Novembro de 2023 (7 meses atrás) • Edgar (US Regulatory) |
Form 8-K/A - Current report: [Amend] Quinta, 31 de Agosto de 2023 (9 meses atrás) • Edgar (US Regulatory) |
Form S-8 - Securities to be offered to employees in employee benefit plans Quinta, 10 de Agosto de 2023 (10 meses atrás) • Edgar (US Regulatory) |
Form 10-Q - Quarterly report [Sections 13 or 15(d)] Quinta, 10 de Agosto de 2023 (10 meses atrás) • Edgar (US Regulatory) |
Form 8-K - Current report Terça, 18 de Julho de 2023 (11 meses atrás) • Edgar (US Regulatory) |
Mais Notícias de Pieris Pharmaceuticals, Inc.
Parece que você não está logado. Clique no botão abaixo para se logar e ver seu histórico recente.
|